Matsuoka Hikaru, Nagai Sadayuki, Kanatani Takayasu, Kouho Nao, Inoue Shintaro, Kenzaka Tsuneaki
Department of Pediatrics, Hyogo Prefectural Tamba Medical Center, Tamba, JPN.
Department of Internal Medicine, Hyogo Prefectural Tamba Medical Center, Tamba, JPN.
Cureus. 2024 Nov 29;16(11):e74779. doi: 10.7759/cureus.74779. eCollection 2024 Nov.
Sublingual immunotherapy (SLIT) leads to the long-term remission of allergic rhinitis and requires long-term daily adherence. There are limited studies on the treatment burden or satisfaction of SLIT among caregivers of children treated using SLIT. We aimed to evaluate the association between the treatment burden and satisfaction for pediatric allergic rhinitis caregivers and the clinical factors of their children's SLIT.
We conducted a questionnaire survey with 115 caregivers of SLIT-treated children from May to August 2023 and retrospectively reviewed their children`s medical records. A single caregiver had at least one child, all undergoing SLIT at the time of the survey. Of the total 139 SLIT-treated children, 78 children over eight years of age were interviewed regarding adherence to SLIT and subjective symptoms of allergic rhinitis. We performed a comparative analysis of caregivers' impressions of SLIT and their children's clinical factors regarding SLIT.
A runny nose was the most common symptom experienced by children before the start of SLIT. After the children started SLIT, 74 (64.3%) of the 115 caregivers felt satisfied and 30 (26.1%) felt burdened by SLIT. The most frequent reasons for being satisfied and burdened by SLIT were because it improved or relieved allergic rhinitis and the preparation and encouragement for children to take SLIT tablets, respectively. Of the 115 caregivers, 96 (83.4%) recommended SLIT to others. A comparative analysis showed that caregivers had already felt burdened from the first one to six months of SLIT initiation and the proportion of caregivers who answered that they felt burdened by SLIT was significantly lower for children with appropriate adherence than for those with inappropriate adherence (11.1% vs. 30.9%,).
Most caregivers of SLIT-treated children reported higher treatment satisfaction than treatment burden. Caregiver burden emerged shortly after the start of SLIT and was also associated with lower adherence in children. This study emphasized the need for strategies to support caregivers and optimize adherence in the early stages of SLIT.
舌下免疫疗法(SLIT)可使过敏性鼻炎长期缓解,且需要长期每日坚持治疗。关于接受SLIT治疗的儿童的照顾者对SLIT的治疗负担或满意度的研究有限。我们旨在评估儿童过敏性鼻炎照顾者的治疗负担与满意度之间的关联以及其子女SLIT的临床因素。
我们在2023年5月至8月对115名接受SLIT治疗儿童的照顾者进行了问卷调查,并回顾性查阅了他们孩子的病历。每位照顾者至少有一个孩子,在调查时所有孩子均在接受SLIT治疗。在总共139名接受SLIT治疗的儿童中,对78名8岁以上的儿童就SLIT的依从性和过敏性鼻炎的主观症状进行了访谈。我们对照顾者对SLIT的印象及其子女SLIT的临床因素进行了比较分析。
流鼻涕是儿童开始SLIT治疗前最常见的症状。在儿童开始SLIT治疗后,115名照顾者中有74名(64.3%)感到满意,30名(26.1%)感到有负担。对SLIT感到满意和有负担的最常见原因分别是它改善或缓解了过敏性鼻炎以及为孩子准备和鼓励孩子服用SLIT片剂。在115名照顾者中,96名(83.4%)向他人推荐了SLIT。比较分析表明,照顾者在SLIT开始的前一至六个月就已经感到有负担,对于依从性良好孩子的照顾者,回答称因SLIT感到有负担的比例显著低于依从性不佳孩子的照顾者(11.1%对30.9%)。
大多数接受SLIT治疗儿童的照顾者报告称治疗满意度高于治疗负担。照顾者的负担在SLIT开始后不久就出现了,并且也与儿童较低的依从性有关。本研究强调了在SLIT早期阶段需要采取策略来支持照顾者并优化依从性。